A focused proteomic analysis of GFAP isoforms in neurodegenerative diseases could aid in understanding the role of these different isoforms per disease and potentially pinpoint discovering disease‐specific GFAP isoforms to develop into novel biomarkers. This evidence concerns the gene GFAP and neurodegenerative disease.